Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AssigneeCelgene Corporation
InventorsGeorge W. Muller, Peter H. Schafer, Hon-Wah Man, Chuansheng Ge
Life of this patent
Estimating the term…
Abstract
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
Claims24
A method of treating a disease or disorder selected from Crohn's Disease or ulcerative colitis, the method comprising administering to a patient having a Crohn's Disease or ulcerative colitis a therapeutically effective amount of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt thereof.
A method of treating Crohn's Disease, which comprises orally administering to a patient having Crohn's Disease about 10 mg to about 100 mg of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione comprising greater than about 97% by weight of (+) isomer, wherein the compound is administered in the form of a tablet or capsule twice daily in equally divided doses.
A method of treating ulcerative colitis, which comprises orally administering to a patient having ulcerative colitis about 10 mg to about 100 mg of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione comprising greater than about 97% by weight of (+) isomer, wherein the compound is administered in the form of a tablet or capsule twice daily in equally divided doses.
Dependencies are inferred from the claim text.